Monografie:

MARINOV, I. Průtoková cytometrie v klinické hematologii. Praha: Triton, 2003. 96 s. ISBN 80-7254-415-2.

MARINOV, I. Průtoková cytometrie v klinické hematologii: 2. přepracované vydání. Praha: Triton, 2008. 152 s. ISBN 978-80-7387-143-7.

Kapitoly v knihách:

IURI MARINOV, ANDREA ILLINGWORTH AND D. ROBERT SUTHERLAND:
Accurate and High Sensitivity Identification of PNH Clones by Flow Cytometry. In Marica Genei (ed.) Multidimensional Flow Cytometry Techniques for Novel Highly Informative Assays, IntechOpen, 2018, s.: 1-17. ISBN 978-1-78923-344-5, http://dx.doi.org/10.5772/intechopen.71286

STÖCKBAUER, P.; MARINOV, I.; MAREČEK, F.; NOVÁK, J.T.; SCHWARZ, J.; KOUBEK, K. Myeloid blind panel flow cytometric analysis : cytokine induced myelomonocytic differentiation-an approach to the analysis of monoclonal antibodies to myeloid cells. In Leukocyte typing VI : white cell differentiation antigens. London: Garland Publishing, 1997, s. 1062-1068. ISBN 0-8153-2745-5.

STÖCKBAUER, P.; HRADCOVÁ, M.; NOVÁK, J.T.; MARINOV, I.; NĚMCOVÁ, J. Monoclonal antibody to a human chronic myeloid leukemia cell line reactive with an antigen in apoptotic cells and apoptotic bodies. In Mason, D. (ed.). Leucocyte typing VII : white cell differentiation antigens. New York: Oxford University Press, 2002, s. 63-68. ISBN 0-19-263252-3.

PROVAZNIKOVA, D.; PESLOVA, G.; MARINOV, I.; BABUSIAK, M.; VYORAL, D.; FUCHS, O. The increased expression of SnoN and undetectable levels of important cell cycle regulators, proteins p21Waf1/Cip1 and p27Kip1 as probable causes of the resistance of ML-2 cells proliferation to transforming growth factor-ßETA1. In YANSON, B. R. (ed.). New research on signal transduction. New York: Nova Science, 2007, s. 189-209. ISBN 1-60021-379-0.

GASOVA, Z.; SPISEK, R.; DOLEZALOVA, L.; MARINOV, I. Extracorporeal photochemotherapy (ECP) in the treatment of patients with cGVHD and CTCL : Czech Republic. In HESHMATI, F. (ed.). Extracorporeal photochemotherapy and transfusion medicine. Paris : European Society for ExtraCorporeal Photochemotherapy, 2008, s. 139-140.

ILLINGWORTH, A.J.; MARINOV, I.; and SUTHERLAND D.R.: Immunophenotyping of Paroxysmal Nocturnal Hemoglobinuria (PNH): In J.Philip McCoy, Jr (ed.) Immunophenotyping, Mehtods and Protocols, Humana Press, 2019, s. 323–354. ISSN 1940-6029, https://doi.org/10.1007/978-1-4939-9650-6

AHMAD AL-ATTAR,; STEPHEN J. RICHARDS,; IURI MARINOV,; ANDREA ILLINGWORTH, AND D. ROBERT SUTHERLAND. High-Sensitivity Detection of Paroxysmal Nocturnal Hemoglobinuria by Multiparameter Flow Cytometry. Manual of Molecular and Clinical Laboratory Immunology, Volume 1, Ninth Edition. Edited by John L. Schmitz, Barbara Detrick, and Maurice R. G. O'Gorman, 2025 American Society for Microbiology. doi:10.1128/9781683674023.ch15.

Články

MARINOV, J.; KOUBEK, K.; STARÝ, J. Immunophenotypic significance of the "lymphoid" CD38 antigen in myeloid blood malignancies. *Neoplasma*, 1993, vol. 40, no. 6, s. 355-358. ISSN 0028-2685. Impact factor: 0.366, rok: 1993.

MARINOV, J.; KOUBEK, K.; STARÝ, J. Expression of CDw12 and CD17 cell surface antigens on leukemic cells from patients with blood malignancies. *Folia Biol*.(Prague), 1993, vol. 39, no. 3, s. 124-128. ISSN 0015-5500. Impact factor: 0.319, rok: 1993.

MARINOV, I.; KOUBEK, K.; STARÝ, J. Lack of expression of adhesion molecules on leukemic cells : possible pathogenetic factor in blood malignancies. *Neoplasma*, 1994, vol. 41, no. 3, s. 141-143. ISSN 0028-2685. Impact factor: 0.354, rok: 1994.

MARINOV, I.; SOUČEK, J. Bovine seminal ribonuclease induces in vitro concentration dependent apoptosis in stimulated human lymphocytes and cells from human tumor cell lines. *Neoplasma*, 2000, vol. 47, no. 5, s. 294-298. ISSN 0028-2685. Impact factor: 0.579, rok: 2000.

MARINOV, I.; LUXOVÁ, A.; TKÁČOVÁ, V.; GAŠOVÁ, Z.; POHLREICH, D.; CETKOVSKÝ, P: Comparison of three single platform methods for CD34+ hematopoietic stem cell enumeration by flow cytometry. *Clin Lab*, 2011, vol. 57, no. 11-12, s. 1031-1035. ISSN: 1433-6510. Impact factor: 0.904, rok 2011

I.MARINOV, M. KOHOUTOVÁ, V. TKÁČOVÁ, D. LYSÁK, M. HOLUBOVÁ, O. STEHLÍKOVÁ, T. ŽELEZNÍKOVÁ, D. ŽONTAR, A. ILLINGWORTH: Intra- and interlaboratory variability of paroxysmal nocturnal hemoglobinuria testing by flow cytometry following the 2012 practical guidelines for high sensitivity paroxysmal nocturnal hemoglobinuria testing, *Cytometry Part B (ClinicalCytometry)*, 2013, no. 84B, s. 229-236, ISSN 1552-4949. Impact factor: 2.231, rok 2012

I. MARINOV, M. KOHOUTOVÁ, V. TKÁČOVÁ, A. PEŠEK, J. ČERMÁK AND P. CETKOVSKÝ: Performance characteristics of consensus approaches for small and minor paroxysmal nocturnal hemoglobinuria clone determination by flow cytometry, *Clin Chem Lab Med,* 2013, vol. 51, no. 11, s. 2133-2139, ISSN 1434-6621. Impact factor: 3.009, rok 2012

I.MARINOV, M. KOHOUTOVÁ, V. TKÁČOVÁ, A. PEŠEK, J. ČERMÁK: Evaluation and Comparison of Different Approaches for Detection of PNH Clones by Flow Cytometry Following the ICCS Guidelines. *Clin Lab,* 2014, vol.60, s: 2017-224 ISSN: 1433-6510. Impact factor: 0.92, rok 2012

I. MARINOV, M. KOHOUTOVÁ, V. TKÁČOVÁ, A. PEŠEK, J. ČERMÁK, P. CETKOVSKÝ: Clinical relevance of CD157 for rapid and cost-effective simultaneous evaluation of PNH granulocytes and monocytes by flow cytometry, *Int J Lab. Hematol.,* 2015, 37(2)231-7.

I. MARINOV, A.J. ILLINGWORTH, M. BENKO, DR. SUTHERLAND: Performance Characteristics of a Non-Fluorescent Aerolysin-Based Paroxysmal Nocturnal (PNH). Assay for Simultaneous Evaluation of PNH Neutrophils and PNH Monocytes by Flow Cytometry, Following Published Guidelines. *Cytometry Part B (ClinicalCytometry),* 2016, 94(2) 257-263. doi: 10.1002/cyto.b.21389.

I. MARINOV, S.J. RICHARDS, A. PEŠEK, A.J. ILLINGWORTH, D.R. SUTHERLAND: Validation of a single tube 3-colour immature red blood cell screening assay for the detection and enumeration of small, medium and large paroxysmal nocturnal haemoglobinuria clones by flow cytometry. *Int J Lab Hematol.,* 2022; 1-7. DOI: 10.1111/ijlh.13877

MARINOV, J.; KOUBEK, K.; STARY, J. Expression of adhesion molecules on the surface of malignant cells and cell lines. Advan. Exp. Med. Biol., 1995, vol. 371A, s. 159-162. ISSN 0065-2598. Impact factor: 0.000.

MARINOV, I. Detection, discrimination and quantification of apoptosis by multiparameter flow cytometry. Klin. Biochem.Metab., 28 (1), 1999, s. 12-17. ISSN 1210-7921. Impact factor: 0.000.

MARINOV, I.; MIKULENKOVÁ, D.; LUXOVÁ, A.; TKÁČOVÁ, V. Imunofenotypizace a diagnostika obtížně klasifikovatelných akutních leukemií: nová diagnostická skupina dle WHO klasifikace 2008. Transfuz. Hemat. dnes, 2010, roč. 16, č. 3, s. 166-171. ISSN 1213-5763. Impact factor: 0.000.

MARINOV, I.; LUXOVÁ, A.; TKÁČOVÁ, V. Standardizované postupy pro analýzu krevních destiček metodou průtokové cytometrie ve vztahu k riziku trombózy a krvácení. Klin. Biochem.Metab., 19 (40), 2011, No. 1, p. 9-14. ISSN 1210-7921. Impact factor: 0.000.

MARINOV I, LUXOVÁ A, TKÁČOVÁ V, MIKULENKOVÁ D, CERMÁK J, CETKOVSKÝ P.: Běžné, standardizované a doporučené postupy v diagnostice a monitorování paroxysmální noční hemoglobinurie průtokovou cytometrií. Vnitr Lek. 2012 Jan;58(1):31-7. Impact factor: 0.000.

SOUČEK, J.; MARINOV, I.; BENEŠ, J.; HILGERT, I.; MATOUŠEK, J.; RAINES, R.T. Immunosuppresive activity of bovine seminal ribonuclease and its mode of action. *Immunobiol.*, 1996, vol. 195, no. 3, s. 271-285. ISSN 0171-2985. Impact factor: 1.320, rok: 1996.

GREBEŇOVÁ, D.; CAJTHAMLOVÁ, H.; BARTOŠOVÁ, J.*; MARINOV*, I.; KLAMOVÁ, H.; FUCHS, O.; HRKAL, Z. Selective destruction of leukaemic cells by photo-activation of 5-aminolaevulinic acid-induced protoporphyrin IX. *J.Photoch.Photobio.B*, 1998, vol. 47, no. 1, s. 74-81. ISSN 1011-1344. Impact factor: 1.365, rok: 1998.

GREBEŇOVÁ, D.; CAJTHAMLOVÁ, H.; HOLADA, K.; *MARINOV*, I.; JIRSA, M.; HRKAL, Z. Photodynamic effect of meso-tetra(4-sulfonatophenyl) porphine on human leukemia cells HEL and HL60, human lymphocytes and bone marrow progenitor cells. *J.Photoch.Photobio.B*, 1997, vol. 39, no. 3, s. 269-278. ISSN 1011-1344. Impact factor: 1.381, rok: 1997.

OTOVÁ, B.; PANCZAK, A.; ŠÍMOVÁ, J.; JANDLOVÁ, T.; BUBENÍK, J.; BLAŽEK, K.; SCHRAMLOVÁ, J.; *MARINOV*, I. Treatment of transplanted spontaneous rat T-cell leukemia with local administration of recombinant murine interleukin-2. *Folia Biol.(Prague)*, 1997, vol. 43, no. 1, s. 25-32. ISSN 0015-5500. Impact factor: 0.522, rok: 1997.

OTOVA, B; SLADKA, M, PANCZAK, A; MARINOV, I.: Biologocal characteristics of spontaneous transplantace T-cell lymphomas in inbred Sprague-Dawley/cub rats. *Transpl. Proc,* 1997, Vol. 29, No 3, 1754-1755, ISSN 0041-1345, Impact factor: 0.952, rok:1997

GAŠOVÁ, Z.; *MARINOV*, I.; HRUBÁ, A.; BENEŠOVÁ, K.; TUREK, P. The efficiency of PBPC collections and the relationship to the precollection concentration of CD 34+ cells in blood. *Transfus.Sci.*, 1999, vol. 20, no. 3, s. 181-188. ISSN 0955-3886. Impact factor: 0.322, rok: 1999.

LEMEŽ, P.; MICHALOVÁ, K.; ZEMANOVÁ, Z.; *MARINOV*, I.; TRPÁKOVÁ, A.; MORAVCOVÁ, J.; JELÍNEK, J. Three cases of near-tetraploid acute myeloid leukemias originating in pluripotent myeloid progenitors. *Leukemia Res.*, 1998, vol. 22, no. 7, s. 581-588. ISSN 0145-2126. Impact factor: 1.348, rok: 1998.

BOBKOVA, K.; OTOVA, B.; *MARINOV*, Y.; MANDYS, V.; PANCZAK, A.; VOTRUBA, I.; HOLY, A. Anticancer effect of PMEDAP : monitoring of apoptosis. *Anticancer Res.*, 2000, vol. 20, no. 2A, s. 1041-1047. ISSN 0250-7005. Impact factor: 1.331, rok: 2000.

SMAHEL, M.; SOBOTKOVA, E.; BUBENIK, J.; SIMOVA, J.; ZAK, R.; LUDVIKOVA, V.; HAJKOVA, R.; KOVARIK, J.; JELINEK, F.; POVYSIL, C.; *MARINOV*, Y.; VONKA, V. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. *Brit.J.Cancer*, 2001, vol. 84, no. 3, s. 374-380. ISSN 0007-0920. Impact factor: 3.942, rok: 2001.

SEDLÁČEK, P.; STARÝ, J.; VODVÁŘKOVÁ, Š.; POLOUČKOVÁ, A.; GAŠOVÁ, Z.; *MARINOV*, I.; FORMÁNKOVÁ, R. Hematopoietic stem cell transplantation in children with hematological malignancies across HLA barriers : reasonable alternative? *Neoplasma*, 2001, vol. 48, no. 4, s. 302-306. ISSN 0028-2685. Impact factor: 0.637, rok: 2001.

POLOUČKOVÁ, A.; VODVÁŘKOVÁ, Š.; KOBYLKA, P.; HRUBÁ, A.; GAŠOVÁ, Z.; *MARINOV*, I.; FALES, I.; SEDLÁČEK, P.; KOZÁK, T.; STARÝ, J. Comparison of two different methods for CD34+ selection and T cell depletion in peripheral blood stem cell grafts : our experiences with cellPro, E rosetting and cliniMACS technique. *Neoplasma*, 2001, vol. 48, no. 5, s. 374-381. ISSN 0028-2685. Impact factor: 0.637, rok: 2001.

HRADCOVÁ, M.; *MARINOV*, I.; NOVÁK, J.; NĚMCOVÁ, J.; STÖCKBAUER, P. Monoclonal antibody to human chronic myeloid leukemia cell line MOLM-7 specifically reacts with an antigen of apoptotic cells. *Leukemia Res.*, 2002, vol. 26, no. 1, s. 45-54. ISSN 0145-2126. Impact factor: 2.115, rok: 2002.

OTOVÁ, B.; SLADKÁ, M.; DAMOISEAUX, J.; PANCZAK, A.; MANDYS, V.; *MARINOV*, I. Relevant animal model of human lymphoblastic leukemia/lymphoma : spontaneous T-cell lymphomas in an inbred Sprague-Dawley rat strain (SD/Cub). *Folia Biol.(Prague)*, 2002, vol. 4, no. 6, s. 213-226. ISSN 0015-5500. Impact factor: 0.615, rok: 2002.

POKORNÁ, D.; ŠMAHEL, M.; JINOCH, P.; JANOUŠKOVÁ, O.; OTÁHAL, P.; KRYŠTOFOVÁ, J.; *MARINOV*, I.; VONKA, V. Zlepšení imunizačního účinku DNA vakcíny pro terapii cervikálního karcinomu. *Chem.Listy*, 2002, roč. 9, č. 4, s. 231-232. ISSN 0009-2770. Impact factor: 0.336, rok: 2002.

ŠTULC, T.; VRABLÍK, M.; KASALOVÁ, Z.; ČEŠKA, R.; *MARINOV*, I. Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. *Atherosclerosis*, 2003, vol. 166, no. 1, s. 197-198. ISSN 0021-9150. Impact factor: 3.603, rok: 2003.

GREBEŇOVÁ, D.; KUŽELOVÁ, K.; SMETANA, K.; PLUSKALOVÁ, M.; CAJTHAMLOVÁ, H.; *MARINOV*, I.; FUCHS, O.; SOUČEK, J.; JAROLÍM, P.; HRKAL, Z. Mitochondrial and endoplasmic

reticulum stress-induced apoptotic pathways are activated by 5-aminolevulinic acid-based photodynamic therapy in HL60 leukemia cells. *J.Photoch.Photobio.B*, 2003, vol. 69, no. 2, s. 71-85. ISSN 1011-1344. Impact factor: 2.275, rok: 2003.

JINOCH, P.; ZAK, R.; JANOUSKOVA, O.; KUNKE, D.; RITTICH, S.; DUSKOVA, M.; SOBOTKOVA, E.; *MARINOV*, I.; ANDELOVA, M.; SMAHEL, M.; VONKA, V. Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2. *Int.J.Oncol.*, 2003, vol. 23, no. 3, s. 775-783. ISSN 1019-6439. Impact factor: 2.536, rok: 2003.

ŠMAHEL, M.; ŠÍMA, P.; LUDVÍKOVÁ, V.; *MARINOV*, I.; POKORNÁ, D.; VONKA, V. Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. *Vaccine*, 2003, vol. 21, no. 11-12, s. 1125-1130. ISSN 0264-410X. Impact factor: 3.007, rok: 2003.

VACKOVÁ, I.; ENGELOVÁ, M.; *MARINOV*, I.; TOMÁNEK, M. Cell cycle synchronization of porcine granulosa cells in G1 stage with mimosine. *Anim.Reprod.Sci.*, 2003, vol. 77, no. 3-4, s. 235-245. ISSN 0378-4320. Impact factor: 1.268, rok: 2003.

GREBEŇOVÁ, D.; KUŽELOVÁ, K.; FUCHS, O.; HALADA, P.; HAVLÍČEK, V.; *MARINOV,* I.; HRKAL, Z. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. *Blood Cell.Mol.Dis.*, 2004, vol. 32, no. 1, s. 262-269. ISSN 1079-9796. Impact factor: 2.549, rok: 2004.

KUŽELOVÁ, K.; GREBEŇOVÁ, D.; PLUSKALOVÁ, M.; *MARINOV*, I.; HRKAL, Z. Early apoptotic features of K562 cell death induced by 5-aminolaevulinic acid-based photodynamic therapy. *J.Photoch.Photobio.B*, 2004, vol. 73, no. 1, s. 67-78. ISSN 1011-1344. Impact factor: 1.841, rok: 2004.

SMETANA, K.; CHAN, P.K.; *MARINOV*, Y.; SOUČEK, J.; HRKAL, Z.; BUSCH, H. A short note on the nucleolar size and density in apoptotic leukemic granulocytic precursors (HL-60 cells). *Life Sci.*, 2004, vol. 75, no. 7, s. 791-796. ISSN 0024-3205. Impact factor: 2.158, rok: 2004.

SMETANA, K.; GREBEŇOVÁ, D.; JIRÁSKOVÁ, I.; DOUBEK, M.; *MARINOV*, Y.; HRKAL, Z. A note on the decreased number and loss of fibrillar centres in nucleoli of apoptotic HL-60 leukaemic granulocytic precursors produced by 5-aminolaevulinic acid-based photodynamic treatment. *Folia Biol.(Prague)*, 2004, vol. 50, no. 1, s. 15-20. ISSN 0015-5500. Impact factor: 0.507, rok: 2004.

SMAHEL, M.; SMAHELOVA, J.; TEJKLOVA, P.; TACHEZY, R.; *MARINOV*, I. Characterization of cell lines derived from tumors induced by TC-1 cells in mice preimmunized against HPV16 E7 oncoprotein. *Int.J.Oncol.*, 2005, vol. 27, no. 3, s. 731-742. ISSN 1019-6439. Impact factor: 2.681, rok: 2005.

STIBRIKOVÁ, G.; MARINOV, I; STÖCKBAUER, P.:An antigen recognized on cells in apoptosis detected by monoclonal antipody 2E12. *Neoplasma*, 2005, vol. 52, no.13, s.12-18. ISSN 0028-2685. Impact factor: 1.247, rok: 2005.

SOBOTKOVÁ, E.; LUDVÍKOVÁ, V.; PETRÁČKOVÁ, M.; DUŠKOVÁ, M.; SMETANA, K.; JELÍNEK, F.; *MARINOV*, I.; VONKA, V. Characteristics of two mouse bcr-abl-transformed cell lines :

I. general properties of the cells. *Folia Biol. (Prague)*, 2005, roč. 51, č. 1, s. 12-18. ISSN 0015-5500. Impact factor: 0.719, rok: 2005.

GAŠOVÁ, Z.; *MARINOV*, I.; VODVÁŘKOVÁ, Š.; BÖHMOVÁ, M.; BHUIYAN-LUDVÍKOVÁ, Z. PBPC collection techniques : standard versus large volume leukapheresis (LVL) in donors and patients. *Transfus.Apher.Sci.*, 2005, vol. 32, no. 2, s. 167-176. ISSN 1473-0502. Impact factor: 1.657, rok: 2005.

KUŽELOVÁ, K.; GREBEŇOVÁ, D.; *MARINOV*, I.; HRKAL, Z. Fast apoptosis and erythroid differentiation induced by Imatinib mesylate in JURL-MK1 cells. *J. Cell. Biochem.*, 2005, vol. 95, no. 2, s. 268-280. ISSN 0730-2312. Impact factor: 3.591, rok: 2005.

BARTOŠOVÁ, J.; KUŽELOVÁ, K.; PLUSKALOVÁ, M.; *MARINOV*, I.; HALADA, P.; GAŠOVÁ, Z. UVA-activated 8-methoxypsoralen (PUVA) causes G2/M cell cycle arrest in Karpas 299 T-lymphoma cells. *J.Photoch.Photobio.B*, 2006, vol. 85, no. 1, s. 39-48. ISSN 1011-1344. Impact factor: 1.909, rok: 2006.

SCHWARZ, J.; MIKULENKOVÁ, D.; ČERMÁKOVÁ, K.; POLANSKÁ, V.; MICHALOVÁ, K.; *MARINOV*, I.; CAMPR, V.; RANSDORFOVÁ, Š.; MARKOVÁ, J.; PAVLIŠTOVÁ, L.; BŘEZINOVÁ, J.; SAJDOVÁ, J.; ŠPONEROVÁ, D.; VOLKOVÁ, Z.; BENEŠOVÁ, K.; ČERMÁK, J.; VÍTEK, A.; CETKOVSKÝ, P. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia : correlations with IgVH gene mutational status and other prognostic markers. *Neoplasma*, 2006, vol. 53, no. 3, s. 219-225. ISSN 0028-2685. Impact factor: 1.247, rok: 2006.

ELKNEROVÁ, K.; LACINOVÁ, Z.; SOUČEK, J.; *MARINOV,* I.; STÖCKBAUER, P. Growth inhibitory effect of the antibody to hematopoietic stem cell antigen CD34 in leukemic cell lines. *Neoplasma*, 2007, vol. 54, no. 4, s. 311-320. ISSN 0028-2685. Impact factor: 1.208, rok: 2007.

GAŠOVÁ, Z.; ŠPÍŠEK, R.; DOLEŽALOVÁ, L.; *MARINOV*, I.; VÍTEK, A. Extracorporeal photochemotherapy (ECP) in treatment of patients with c-GVHD and CTCL. *Transfus.Apher.Sci.*, 2007, vol. 36, no. 2, s. 149-158. ISSN 1473-0502. Impact factor: 0.970, rok: 2007.

BÉNÉ, M.C.; CASTOLDI, G.; DEROLF, A.; GARAND, R.; HAAS, T.; HAFERLACH, T.; KNAPP, W.; KUHLEIN, E.; LEMEŽ, P.; LUDWIG, W.D.; *MARINOV*, I.; MATUTES, E.; MICHALOVÁ, K.; PORWIT-MACDONALD, A.; ORFAO, A.; SCHOCH, C.; TALMANT, P.; VAN´T VEER, M.B.; ZEMANOVÁ, Z.; ZÜHLSDORF, M. Near-tetraploid acute myeloid leukemias : an EGIL retrospective study of 25 cases. *Leukemia*, 2006, vol. 20, no. 4, s. 725-728. ISSN 0887-6924. Impact factor: 6.146, rok: 2006.

ŠTULC, T.; VRABLÍK, M.; KASALOVÁ, Z.; *MARINOV*, I.; SVOBODOVÁ, H.; ČEŠKA, R. Leukocyte and endothelial adhesion molecules in patients with hypercholesterolemia : the effect of atorvastatin treatment. *Physiol.Res.*, 2008, vol. 57, no. 2, s. 185-194. ISSN 0862-8408. Impact factor: 1.653, rok: 2008.

LAKATOSOVA-ANDELOVA, M.; JINOCH, P.; DUSKOVA, M.; *MARINOV,* I.; VONKA, V. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macropage colony stimulation factor derived from mouse HPV-16-transformed cells. *Int.J.Oncol.*, 2008, vol. 32, no. 1, s. 265-271. ISSN 1019-6439. Impact factor: 2.234, rok: 2008.

VRABLIK, M.; STULC, T.; KASALOVA, Z.; *MARINOV*, I.; MALIK, J.; SIMEK, J.; SVOBODOVA, H.; ZIDKOVA, K.; CESKA, R. Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. *Nutr.Res.*, 2007, vol. 27, no. 3, s. 181-185. ISSN 0271-5317. Impact factor: 0.683, rok: 2007.

MOTOVSKA, Z.; WIDIMSKY, P.; PETR, R.; BILKOVA, D.; *MARINOV*, I.; SIMEK, S.; KALA, P. Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. *Int. J. Cardiol.*, 2010, vol. 144, no. 2, s. 255-257. ISSN 0167-5273. Impact factor: 3.469, rok: 2009.

MOTOVSKA, Z.; WIDIMSKY, P.; PETR, R.; BILKOVA, D.; *MARINOV*, I.; SIMEK, S.; KALA, P. Factors influencing clopidogrel efficacy in patiens with stable coronary artery dinase undergoing elative percutaneous coronary intervention: statin´s advantage and the smoking paradox. *Journal of Cardiovascular Pharmacology*, 2009, vol. 53, no. 5, s. 368-372. ISSN: 01602446. Impact factor: 2.826

MOTOVSKA, Z.; WIDIMSKY, P.; *MARINOV*, I.; PETR, R.; HAJKOVA, J.; KVASNICKA, J. Clopidogrel resistance "Live" : the risk of stent thrombosis should be evaluated before procedures. Thromb. J. 2009, vol. 7, no. 6, s. 1-6. ISSN 1477-9560. Impact factor: 1.24.

MOTOVSKA, Z.; WIDIMSKY, P.; KVASNICKA, J.; PETR, R.; BILKOVA, D.; HAJKOVA, J.; MARINOV, I.; SIMEK, S.; KALA, P. High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism : a genetic substudy of PRAGUE-8 trial. Blood Coagul.Fibrin., 2009, vol. 20, no. 4, s. 257-262. ISSN 0957-5235. Impact factor: 1.246, rok: 2009.

SVOBODOVÁ, H.; ŠTULC, T.; KASALOVÁ, Z.; DOLEŽALOVÁ, R.; *MARINOV*, I.; ČAPEK, P.; ČEŠKA, R. The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus. *Physiol.Res.*, 2009, roč. 58, č. 5, s. 701-707. ISSN 0862-8408. Impact factor: 1.430, rok: 2009.

LYSÁK, D.; KALINA, T.; MARTÍNEK, J.; PIKALOVÁ, Z.; VOKURKOVÁ, D.; JAREŠOVÁ, M.; *MARINOV*, I.; ONDREJKOVÁ, A.; ŠPAČEK, M.; STEHLÍKOVÁ, O. Interlaboratory variability of CD34+ stem cell enumeration : a pilot study to national external quality assessment within the Czech Republic. *Int. J. Lab. Hematol.*, 2010, vol. 32, no. 6 Pt.1, s. e229-e236. ISSN 1751-5521. Impact factor: 1.304, rok: 2009.

GAŠOVÁ, Z.; BHUIYAN-LUDVÍKOVÁ, Z.; BÖHMOVÁ, M.; *MARINOV*, I.; VACKOVÁ, B.; POHLREICH, D.; TRNĚNÝ, M. PBPC collections : management, techniques and risks. *Transfus. Apher. Sci.*, 2010, vol. 43, no. 2, s. 237-243. ISSN 1473-0502. Impact factor: 0.938, rok: 2009.

BÉNÉ, MC; NEBE, PB; BULDINI,B; BUMBEA,H; KERN,W; LACOMBE,F; LEMEZ,P; MARINOV,I; MATUTES, E; MAYNADIE,M; OELSCHLAGEL,U; ORFAO,A; SCHABATH,R; SOLENTHALER,M; TSCHURTSCHENTHALER, G;VLADAREANU, AM; ZINI, G; PORWIT, A. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a concensus proposal of the European LeukemiaNet Work Package 10. *Leukemia,* 2011, 1-8. Impact factor: 8,296, rok 2009

PETR, LEMEŽ; HANA, KLAMOVÁ; ZUZANA, ZEMANOVÁ; IURI, MARINOV; OTA, FUCHS; JIŘÍ, SCHWARZ; JANA BŘEZINOVÁ; DANA PROVAZNÍKOVÁ; ARNOŠT, KOSTE4KA; JANA MARKOVÁ; KYRA MICHALKOVÁ; JAROSLAV, JELÍNEK: Unusually Long Survival of a 67-

Year-Old Patient with Near Tetraploid Acute Myeloid Leukemia M0 without Erythroblastic and megakaryocytic Dysplasia. *ActaHematol,* 2011;126:129-134. ISSN: 0001-5792. Impact factor: 1,316, rok 2010

ELKNEROVÁ, K.; MYSLIVCOVÁ D.; LACINOVÁ Z.; MARINOV, I.; UHERKOVÁ, L.; STÖCKBAUER, P.: Epigenetic modulation of gene expression of human leukemia cell lines-induction of cell death and senescence. *Neoplasma*, 2011, vol. 58, no.1, s. 34-44. ISSN 0028-2685. Impact factor: 1.449, rok: 2010

PROVAZNIKOVA, D.; RITTICH, S.; MALINA, M.; SEEMAN, T.; MARINOV, I.; RIEDL, M.; HRACHOVINOVA, I.:Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. *Pediatr. Nephrol,* 2012, vol. 27, no. 1, s 1-9. ISSN: 0931041X. Impact Factor: 2,183, rok 2010

TOMAŠ ŠTULC, RICHARD ČEŠKA, IURI MARINOV, JAN ŠKRHA: The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharides receptor CD14 in type 2 diabetes mellitus. *Neuroendocrinol Lett* 2012; 33 (Suppl. 2): 73-77

L. UHERKOVÁ, I. VANČUROVÁ, I. VYHLÍDKOVÁ, M. PLESCHNEROVÁ, I. ŠPIČKA, R. MIHALOVÁ, J. BŘEZÍNOVÁ, Z. HODNÝ, K. ČERMÁKOVÁ, V. POLANSKÁ, I. MARINOV, P.L. JEDELSKÝ, K. KUŽELOVÁ, P. STÖCKBAUER: Novel human multiple myeloma cell line UHKT-893. *Leukemia Research*, 2013, vol. 37, s.:320-326, ISSN 0145-2126, Impact factor: 2,764, rok 2012

J. POLAK, H. HAJKOVÁ, C. HASKOVEC, H. CECHOVA, I. MARINOV, D. MIKULNEKOVA, J. MARKOVA, M. MARKOVA, A. VITEK, V. VALKOVA: Quantitative monitoring of WT1 expression in peripheral blood efore and after allogeneic stem cell transplantation for acute myeloid leukemeia-a useful tool for early detection of minimal residual dinase. *Neuplasma*, 60,1,2013

T. ŠTULC[1], H. SVOBODOVÁ[1], Z. KRUPIČKOVÁ[1], R. DOLEŽALOVÁ[1], I. MARINOV[1], R. ČEŠKA. Rosiglitazone Influences the Expression of Leukocyte Adhesion Molecules and CD14 Receptor in type 2 Daibetes Mellitus Patients. *Physiol.Res.*, 2014, vol. 63 (Suppl. 2), s. 293-298. ISSN 0862-8408. Impact factor: 1.653, rok: 2008.

ŠÁLEK C, FOLBER F, FROŇKOVÁ E, PROCHÁZKA B, **MARINOV I**, CETKOVSKÝ P, MAYER J, DOUBEK M; Czech Leukemia Study Group - for Life: Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia. Eur J Haematol, 2016, 96(3),276-84, doi: 10.1111/ejh.12587. Epub 2015 Jun 22.

PÍSAČKA M, MARINOV I, KRÁLOVÁ M, KRÁLOVÁ J, KOŘÁNOVÁ M, BOHONĚK M, SOOD C, OCHOA-GARAY G. FY*A silencing by the GATA-motif variant FY*A(-69C) in a Caucasian family. Transfusion. 2015 Nov;55(11):2616-9. doi: 10.1111/trf.13221. Epub 2015 Jul 14

RAWSTRON AC, FAZI C, AGATHANGELIDIS A, VILLAMOR N, LETESTU R, NOMDEDEU J, PALACIO C, STEHLIKOVA O, KREUZER KA, LIPTROT S, O'BRIEN D, DE TUTE RM, **MARINOV I**, HAUWEL M, SPACEK M, DOBBER J, KATER AP, GAMBELL P, SOOSAPILLA A, LOZANSKI G, BRACHTL G, LIN K, BOYSEN J, HANSON C, JORGENSEN JL, STETLER-STEVENSON M, YUAN C, BROOME HE, RASSENTI L, CRAIG F, DELGADO J, MORENO C, BOSCH F, EGLE A, DOUBEK M, POSPISILOVA S, MULLIGAN S, WESTERMAN D, SANDERS CM, EMERSON R, ROBINS HS, KIRSCH I, SHANAFELT T, PETTITT A, KIPPS TJ, WIERDA WG, CYMBALISTA F, HALLEK M, HILLMEN P, MONTSERRAT E, GHIA P. A comple-mentary

role of multiparameter flow cytometry and high-throughput sequencing for mini-mal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7

POLIVKOVA V, ROHON P, KLAMOVA H, CERNA O, DIVOKA M, CURIK N, ZACH J, NOVAK M, MARINOV I, SOVERINI S, FABER E, MACHOVA POLAKOVA K. Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. PLoS One. 2016 May 23;11(5):e0155959. doi: 10.1371/journal.pone.0155959. eCollection 2016.

ILLINGWORTH A, MARINOV I, SUTHERLAND DR, WAGNER-BALLON O, DELVECCHIO L. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 3 - data analysis, reporting and case studies. Cytometry Part B 2018; 94B: 49-66. doi: 10.1002/cyto.b.21610

SUTHERLAND DR, ILLINGWORTH A, MARINOV I, ORTIZ F, ANDREASEN J, PAYNE D, WALLACE PK, KEENEY M. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 - reagent selection and assay optimization for high-sensitivity testing. Cytometry Part B 2018; 94B: 23-48. doi: 10.1002/cyto.b.21610

SUTHERLAND DR, ORTIZ F, QUEST G, ILLINGWORTH A, BENKO M, NAYYAR R, MARINOV I. High-sensitivity 5-, 6-, and 7-color PNH WBC assays for both Canto II and Navios platforms. Cytometry Part B 2018; 94B: 637-651

SUTHERLAND DR, ILLINGWORTH AJ, WHITBY L, MARINOV I. Re Gatti et al (Eur J Haematol 2017 Mar 23. Doi: 10.1111/ejh.12885). Eur J Haematol 2018 Dec;101(6):804-806.

MIKLIK R, KNOT J, KRALIK R, KAMENIK M, JARKOVSKY J, MARINOV I, MOTOVSKA Z. Pharmacodynamics of prasugrel and tricagrelor in patients with acute coronary syndrome and the effect of switching to clopidogrel for economic and other reasons; platelet reactivity sub-study of the multicenter randomized Prague-18 trial. Journal of the American college of cardiology 2018 Vol 71, Volume: 71 Issue: 11 Pages: 68-68 Supplement: S Meeting Abstract: A68. DOI: 10.1016/S0735-1097(18)30609-0

D.ROBERT SUTHERLAND, STEPHEN RICHARDS, FERNANDO ORTIZ, RAKESH NAYAAR, MIROSLAV BENKO, IURI MARINOV, ANDREA WILLINGWORTH. CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria. Cytometry Part B 2019; 94B: 637-651

GASOVA, Z VACKOVA, B BHUIYAN-LUDVIKOVA, Z, BOHMOVA, M, SLOUKOVA, M MARINOV, I PECHERKOVA, P. Standard and Large volume leukapheresis (LVL) using the new CMNC protocol Spectra Optia. Bone marrow transplantation 2018 Vol. 53 Pages: 786-787 Supplement: S Meeting Abstract: P861.

PESEK A, KOHOUTOVA M, VOJTOVA P, MARINOV, I. Interlaboratory variability for GPI-deficiency testing by flow cytometry following a regional external quality assessment program. Int. J. Lab. Hematology 2018. Vol 40 Pages: 115-115 Supplement: 2 Special Issue: SI

ILLINGWORTH AJ, MARINOV I., SUTHERLAND DR. Sensitive and accurate identification of PNH clones based on ICCS/ESCCA PNH Consensus Guidelines-A summary. Int J Lab Hematol. 2019, Suppl. 1:73-81. doi: 10.1111/ijlh.13011

ILLINGWORTH AJ, MARINOV I., SUTHERLAND DR. Immunophenotyping of Paroxysmal Nocturnal Hemoglobinuria (PNH). Mehtods Mol. Biol. 2019; 2032:323-354. doi: 10.1007/978-1-4939-9650-6_18.

SUTHERLAND DR, RICHARDS SJ, ORTIZ F, NAYAAR R, BENKO M, MARINOV I, ILLINGWORTH A. CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom. 2020 Mar;98(2):179-192. doi: 10.1002/cyto.b.21853. Epub 2019 Nov 8. PMID: 31705743

VALKOVA V, VYDRA J, MARKOVA M, CEROVSKA E, VRANA M, MARINOV I, CECHOVA H, CETKOVSKY P, VITEK A, SALEK C. WT1 Gene Expression in Peripheral Blood Before and After Allogeneic Stem Cell Transplantation is a Clinically Relevant Prognostic Marker in AML - A Single-center 14-year Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e145-e151. doi: 10.1016/j.clml.2020.09.008. Epub 2020 Oct 12.PMID: 33160932

MOTOVSKA Z, HLINOMAZ O, MROZEK J, KALA P, GEISLER T, HROMADKA M, AKIN I, PRECEK J, KETTNER J, CERVINKA P, MONTALESCOT G, JARKOVSKY J, BELOHLAVEK J, BIS J, MATEJKA J, VODZINSKA A, MUZAFAROVA T, TOMASOV P, SCHEE A, BARTUS S, ANDRASOVA A, OLIVIER CB, KOVARIK A, OSTADAL P, DEMLOVA R, SOUCKOVA L, VULEV I, COUFAL Z, KOCHMAN J, MARINOV I, KUBICA J, DUCROCQ G, KARPISEK M, KLIMSA Z, HUDEC M, WIDIMSKY P, BHATT DL, GROUP DS. Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. EuroIntervention. 2024 Oct 21;20(20):e1309-e1318. doi: 10.4244/EIJ-D-24-00203.